Care Friction Blueprint | August 2026
Build a reliable path from symptom burden to sustained nutrition
Gastroparesis Awareness Month 2026 gives healthcare leaders a focused opportunity to examine a condition that crosses gastroenterology, endocrinology, nutrition, pharmacy, emergency care, primary care, behavioral health, and daily life. Awareness becomes useful when patients can move through recognition, objective diagnosis, individualized treatment, and continuing support without preventable delay or disbelief.
Hear the burden.
Confirm the condition.
Protect nutrition.
Coordinate the response.
Date source: IFFGD
Author: Greg Wahlstrom, MBA, HCM
The executive signal: the burden is clinical and operational
The International Foundation for Gastrointestinal Disorders confirms August as Gastroparesis Awareness Month. IFFGD established the observance to improve understanding of diagnosis, treatment, and quality-of-life needs. Its standing page does not assign a 2026 campaign theme, so leaders should avoid manufacturing one and instead use the month to make the real care pathway easier to navigate.
Gastroparesis involves symptoms associated with food remaining in the stomach and objectively delayed gastric emptying when mechanical obstruction is absent. Symptoms can include early fullness, prolonged fullness after a meal, nausea, vomiting, bloating, upper abdominal pain, heartburn, and poor appetite. The National Institute of Diabetes and Digestive and Kidney Diseases identifies dehydration, malnutrition, difficult glucose control, bezoars, unintended weight loss, and reduced quality of life among possible complications.
Manage the four clocks patients experience
Traditional service-line reports count visits and procedures. Patients experience elapsed time, repeated explanations, food intolerance, missed work, and uncertainty. A gastroparesis pathway should therefore manage four connected clocks.
From first symptoms to a credible clinical response
Train primary, emergency, diabetes, and surgical teams to recognize concerning patterns, medication effects, dehydration, malnutrition, and urgent warning signs. The NIDDK symptom and cause guide is a practical patient-education reference, but screening must route to clinical evaluation rather than label every case as gastroparesis.
From referral to a complete diagnostic study
The 2025 American Gastroenterological Association guideline supports four-hour gastric emptying testing for diagnosis. NIDDK describes gastric emptying scintigraphy and breath testing as options. Executives should monitor scheduling delay, test completion, protocol adherence, result turnaround, and the next appointment after an abnormal result.
From diagnosis to a workable nutrition and medication plan
Nutrition support is not a handout at checkout. Ensure timely access to a registered dietitian, individualized education, hydration planning, diabetes coordination, and escalation when oral intake is inadequate. NIDDK treatment guidance outlines dietary, medication, feeding, and procedural approaches that clinicians may consider according to cause, severity, complications, and response.
From initial plan to safer daily living
Define who receives symptom messages, weight changes, glucose concerns, medication adverse effects, and urgent calls. Build refill review, pharmacy follow-up, access to specialty consultation, and clear emergency guidance into the pathway. Continuity matters because symptoms may fluctuate even when a treatment plan is clinically appropriate.
A service blueprint for reliable gastroparesis care
| Journey stage | Common friction | Executive control | Measure to review |
|---|---|---|---|
| Recognition | Symptoms minimized or routed repeatedly | Standard triage, warning signs, and referral criteria | Referral source and time to first appropriate visit |
| Diagnosis | Incomplete or delayed testing | Standard protocol, preparation, capacity, and result ownership | Order-to-test days, completion rate, protocol exceptions |
| Nutrition | Dietitian access occurs after deterioration | Early nutrition screening and tiered referral | Nutrition visit timeliness, weight and hydration escalation |
| Medication | Duration and adverse-effect risk become invisible | Medication reconciliation, indication, monitoring, and reassessment | Documented review and follow-up after therapy changes |
| Continuity | No clear owner between specialties | Named coordinator and closed-loop messaging | Unanswered messages, avoidable urgent use, missed follow-up |
| Equity | Testing, food, travel, or language barriers | Barrier screening and segmented access data | Completion and delay by language, geography, payer, and disability |
Use locally defined denominators and balance measures. A smaller metric set with reliable definitions is more useful than a large dashboard that cannot trigger action.
Equity lives in the logistics
A referral is not access when a patient cannot complete a four-hour study, reach a motility specialist, afford recommended foods or liquid nutrition, obtain language support, or leave work for repeated appointments. Segment the pathway by language, geography, disability, payer, and referral source, then ask why a difference appears. Offer preparation instructions in accessible formats, coordinate testing with other visits when clinically feasible, use navigation for missed handoffs, and connect patients with financial and community resources. Leaders should also examine whether rural and safety-net partners can obtain timely consultation and clear return plans. Equity improves when the operating model removes predictable burdens instead of treating noncompletion as a patient failure.
Medication governance deserves specific attention. The February 2026 FDA label for Reglan retains a boxed warning for tardive dyskinesia, calls for the shortest treatment duration and periodic reassessment, and advises avoiding cumulative metoclopramide treatment beyond 12 weeks in diabetic gastroparesis unless longer use is unavoidable. This is a clinical decision, but executive teams can ensure that indication, duration, monitoring, patient counseling, and follow-up are visible in the medication-use system.
Use August as a four-week learning sprint
Campaign activity should produce a durable operational change. Connect the month to the enterprise rhythm described in The 2026 Hospital Operations Playbook: one accountable owner, shared definitions, visible constraints, and a clear escalation path.
Invite patients, caregivers, clinicians, dietitians, and pharmacists to identify the hardest handoffs and longest waits.
Review diagnostic protocols, urgent criteria, nutrition access, medication controls, and communication ownership.
Test a focused change such as protected dietitian access, scheduling escalation, or closed-loop result outreach.
Share what changed, what patients experienced, the measure that moved, and the next accountable action.
Five questions for the board and executive team
- Where do patients wait longest between recognition, testing, nutrition support, and specialty follow-up?
- Can we identify patients at risk of dehydration, malnutrition, glucose instability, or medication harm before an urgent visit?
- Do patients know who owns the plan and how to escalate worsening symptoms or inability to maintain intake?
- Which populations have lower test completion or longer access times, and what barrier explains the difference?
- What patient-reported signal reaches leadership, and which operational decision has it changed?
Executive conclusion
Gastroparesis Awareness Month 2026 should leave more than content on a communications calendar. It should leave a clearer diagnostic route, earlier nutrition support, safer medication oversight, better access to expertise, and a patient experience built on credibility and continuity. The most meaningful awareness outcome is a system that hears the burden sooner and responds with coordinated, evidence-informed care.
This executive brief is educational and does not replace individualized medical evaluation or treatment. People experiencing severe or worsening symptoms should seek guidance from a qualified clinician.